GVR Report cover Influenza Vaccine Market Size, Share & Trends Report

Influenza Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type, By Indication, By Age Group, By Route Of Administration, By Distribution Channel, And By Region, And Segment Forecasts, 2023 To 2030

  • Report ID: GVR453673
  • Number of Pages: 0
  • Format: Electronic (PDF)

Influenza is a major global public health concern and according to WHO, affects around 100 million individuals annually, causing around 5 million cases of severe illness and around 600,000 deaths globally along with a huge economic burden. Vaccination is crucial to slow down the incidence and to lower the severity of pandemic situations caused by viral infections.

There was an inadvertent slowdown in vaccination drives across the globe due to the incidence of COVID-19 pandemic situation. Nevertheless, many countries launched joint vaccination drives against COVID-19 and seasonal influenza together. WHO recommends such joint vaccination drives due to better reach and other potential advantages. Many pharmaceutical giants expanded their collaborations made for the development of COVID-19 vaccines to include indications for respiratory and influenza viruses. For instance, in November 2022, Arcturus Therapeutics Holdings Inc. collaborates with CSL Seqirus for mRNA technology to support the development and production of vaccines for SARS-CoV-2 (COVID-19), influenza, and prevalent respiratory viral infections.

Quadrivalent vaccines essentially combat two Influenza-A viruses and two Influenza-B viruses, therefore they are most preferred for vaccination regimes. Companies are working significantly towards carrying out research studies that involve developing novel quadrivalent vaccines. For instance, in September 2022, Pfizer Inc. declared the start of its pivotal phase-3 clinical trial study for the evaluation of attributes like the safety and efficacy of its quadrivalent modified RNA (modRNA) candidate with over 25,000 healthy participants after achieving promising results from the first two phases.

Oral vaccines are preferred over vaccine injections because of the flexibility it offers for production, storage conditions, logistics, and administration. The oral forms of vaccinations may also potentially increase the rate of administration to the mass population. Research efforts are underway for devising novel oral vaccines that are equally efficient to injectable vaccines. For instance, in July 2019, Vaxart, Inc., collaborated with Janssen Vaccines B.V. for the evaluation of Vaxart’s oral vaccine platform with a potential candidate that is used in the form of a room temperature-stable tablet for Janssen’s universal influenza vaccination program.

Due to the emergence of virus strains, researchers are working towards devising a vaccination strategy that could combat multiple strains of the influenza virus and achieve long-lasting immunity in an individual. For instance, in March 2022, Researchers at the National University of Singapore and Monash University, Melbourne collaboratively published research in the ‘Proceedings of the National Academy of Sciences’ featuring a platform to effectively deliver vaccine candidate M2e to the immune cells so as to achieve long-lasting immunity against multiple strains of the virus.

Moreover, in May 2022, Osivax, signed a collaboration agreement with the National Institute of Allergy and Infectious Diseases (part of the NIH), to carry out a preclinical evaluation integrating Osivax’s T-cell-based influenza candidate, with a broad spectrum influenza vaccine candidates of the NIAID Research Center.

Measuring the vaccine’s potency and efficacy is crucial to gauge the immunity it offers against infection and is ascertained by the random administration of potential vaccine candidates to healthy volunteers through numerous clinical trials at different stages. For instance, in September 2022, the RAIVEN (Randomized Assessment of Influenza Vaccine Efficacy Network) was instated. RAIVEN is a collaborative effort between the Centre for Disease Control in the U.S. states for carrying out randomized trials.

Many countries across the globe are investing consistent efforts to achieve autonomy in vaccine production to rule out dependency on other countries for vaccine supply. Vaccines are most efficiently designed by research efforts by various research groups across research institutes and pharmaceutical giants. For instance, in May 2022, Blue Water Vaccines, Inc. partnered with the Center for R&D in Immunobiologics (CeRDI), Brazil for the development of a universal influenza vaccine candidate, so as to advance vaccine development based on novel adjuvant formulations and cell-cultures.

Influenza Vaccine Market: Segmentation



By Vaccine type

  • Inactivated
  • Live Attenuated

By Indication

  • Quadrivalent
  • Trivalent

By Age group

  • Paediatric
  • Adult

By Route of Administration

  • Injection

Nasal Spray

By Distribution channel

  • Hospitals & Pharmacy
  • Government & Institutional supply
  • Other

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


Some of the major companies in the market include GlaxoSmithKline Plc, Biodiem, Sanofi, AstraZeneca, CSL Limited, Emergent Biosolutions, BIKEN Co, Ltd., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Merck & Co., Inc., Sinovac Biotech Ltd., Novartis Ag, Viatris Inc., and Pfizer Inc.

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon